Company overview
Equillium is a clinical-stage biotechnology company developing novel immunomodulatory therapeutics targeting immuno-inflammatory pathways for severe autoimmune and inflammatory disorders. Key pipeline assets include itolizumab, licensed from Biocon for acute graft-versus-host disease and ulcerative colitis, and EQ504, a potent aryl hydrocarbon receptor modulator for skin, gastrointestinal, and lung diseases. The company focuses on non-immunosuppressive mechanisms to restore immune balance with high unmet medical need.
Equillium - Home is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include equillium, itolizumab, eq504, autoimmune therapeutics, inflammatory disorders, ahr modulator.
Structured facts
- Website
- https://www.equilliumbio.com
- Markets served
- United States & Americas
- Keywords
- equillium, itolizumab, eq504, autoimmune therapeutics, inflammatory disorders, ahr modulator, graft-versus-host disease, ulcerative colitis
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What are Equillium's main therapeutic areas and pipeline assets?
- Equillium develops therapeutics for severe autoimmune and inflammatory disorders, including itolizumab for acute graft-versus-host disease (aGVHD) and ulcerative colitis (UC), and EQ504, an aryl hydrocarbon receptor (AhR) modulator for skin, gastrointestinal, and inflammatory lung diseases.
- What is the regulatory status of Equillium's lead candidates?
- Itolizumab has received FDA feedback on Accelerated Approval pathway for first-line aGVHD treatment and showed positive Phase 2 data in UC with 23.3% clinical remission. EQ504 is advancing into clinic with up to $50M financing.
- What are Equillium's geographic rights and partnerships?
- Equillium holds exclusive rights to develop and commercialize itolizumab in the U.S., Canada, Australia, and New Zealand through a license agreement with Biocon.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
